Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis
WILSCHANSKI, M, MILLER, L. L, COHEN-CYMBERKNOH, M, MILLER, N. L, REHA, A, NORTHCUTT, V. J, HIRAWAT, S, DONNELLY, K, ELFRING, G. L, AJAYI, T, KEREM, E, SHOSEYOV, D, BLAU, H, RIVLIN, J, AVIRAM, M, COHEN, M, ARMONI, S, YAAKOV, Y, PUGATCH, T
Published in The European respiratory journal (01.07.2011)
Published in The European respiratory journal (01.07.2011)
Get full text
Journal Article
Choroidal flame
Hirawat, Raj, Mohankumar, Arthi, Nagesha, C
Published in Indian journal of ophthalmology (01.06.2022)
Published in Indian journal of ophthalmology (01.06.2022)
Get full text
Journal Article
Changes in confocal microscopy in glaucoma patients after intraocular pressure reduction with medical therapy
Hirawat, Raj S, Aron, Neelima, Mahalingam, Karthikeyan, Gupta, Viney, Angmo, Dewang, Dada, Tanuj, Titiyal, Jeewan S, Sharma, Namrata, Sihota, Ramanjit
Published in Indian journal of ophthalmology (01.06.2024)
Published in Indian journal of ophthalmology (01.06.2024)
Get full text
Journal Article
Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial
Kerem, Eitan, Dr, Hirawat, Samit, MD, Armoni, Shoshana, BSN, Yaakov, Yasmin, MSc, Shoseyov, David, MD, Cohen, Michael, MD, Nissim-Rafinia, Malka, PhD, Blau, Hannah, MD, Rivlin, Joseph, MD, Aviram, Micha, MD, Elfring, Gary L, MS, Northcutt, Valerie J, MS, Miller, Langdon L, MD, Kerem, Batsheva, PhD, Wilschanski, Michael, MBBS
Published in The Lancet (British edition) (30.08.2008)
Published in The Lancet (British edition) (30.08.2008)
Get full text
Journal Article
Discovery and development of novel therapies in advanced breast cancer: rapid development of ribociclib
Germa, C., Miller, M., Mukhopadhyay, P., Hewes, B., Caponigro, G., Scherer, S.J., Hirawat, S.
Published in Annals of oncology (01.08.2017)
Published in Annals of oncology (01.08.2017)
Get full text
Journal Article
Alpelisib (ALP) + fulvestrant (FUL) for advanced breast cancer (ABC): Results of the phase III SOLAR-1 trial
André, F., Ciruelos, E.M., Rubovszky, G., Campone, M., Loibl, S., Rugo, H.S., Iwata, H., Conte, P., Mayer, I.A., Kaufman, B., Yamashita, T., Lu, Y.-S., Inoue, K., Takahashi, M., Pápai, Z., Longin, A.-S., Mills, D., Wilke, C., Hirawat, S., Juric, D.
Published in Annals of oncology (01.10.2018)
Published in Annals of oncology (01.10.2018)
Get full text
Journal Article
Quantitative cough assessment in cystic fibrosis (CF)
Kerem, E, Wilschanski, M, Elfring, G.L, Hirawat, S, Pugatsch, T, Reha, A, Constantine, S, Peltz, S.W, Miller, L.L
Published in Journal of cystic fibrosis (01.06.2008)
Published in Journal of cystic fibrosis (01.06.2008)
Get full text
Journal Article
G.P.3.05 Phase 2 study of PTC124 for nonsense mutation suppression therapy of Duchenne muscular dystrophy (DMD)
Bönnemann, C, Finkel, R, Wong, B, Flanigan, K, Sampson, J, Sweeney, L, Reha, A, Elfring, G, Miller, L, Hirawat, S
Published in Neuromuscular disorders : NMD (2007)
Published in Neuromuscular disorders : NMD (2007)
Get full text
Journal Article
PTC124 treatment over 3 months improves pharmacodynamic and clinical parameters in patients with nonsense-mutation-mediated CF
Wilschanski, M, Armoni, S, Yaakov, Y, Blau, H, Shoseyov, D, Cohen, M, Hirawat, S, Elfring, G.L, Reha, A, Miller, L.L, Kerem, E
Published in Journal of cystic fibrosis (01.06.2008)
Published in Journal of cystic fibrosis (01.06.2008)
Get full text
Journal Article
PTC124 induces CFTR full-length production and activity in children with nonsense-mutation-mediated CF
Sermet-Gaudelus, I, Leal, T, De Boeck, K, Casimir, G, Hanssens, L, Hage, P, Roussel, D, Mogenet, A, Hirawat, S, Elfring, G.L, Constantine, S, Miller, L.L
Published in Journal of cystic fibrosis (01.06.2008)
Published in Journal of cystic fibrosis (01.06.2008)
Get full text
Journal Article
41 PTC124 activity in CF patients carrying stop mutations: results of a phase 2 study
Kerem, E, Hirawat, S, Armoni, S, Yaakov, Y, Blau, H, Rivlin, J, Aviram, M, Shoseyov, D, Cohen, M, Northcutt, V, Elfring, G, Miller, L, Wilschanski, M
Published in Journal of cystic fibrosis (2007)
Published in Journal of cystic fibrosis (2007)
Get full text
Journal Article
PI3K inhibitors as new cancer therapeutics: implications for clinical trial design
Massacesi, Cristian, Di Tomaso, Emmanuelle, Urban, Patrick, Germa, Caroline, Quadt, Cornelia, Trandafir, Lucia, Aimone, Paola, Fretault, Nathalie, Dharan, Bharani, Tavorath, Ranjana, Hirawat, Samit
Published in OncoTargets and therapy (01.01.2016)
Published in OncoTargets and therapy (01.01.2016)
Get full text
Journal Article
LBA3_PRAlpelisib (ALP) + fulvestrant (FUL) for advanced breast cancer (ABC): Results of the phase III SOLAR-1 trial
André, F, Ciruelos, E M, Rubovszky, G, Campone, M, Loibl, S, Rugo, H S, Iwata, H, Conte, P, Mayer, I A, Kaufman, B, Yamashita, T, Lu, Y -S, Inoue, K, Takahashi, M, Pápai, Z, Longin, A-S, Mills, D, Wilke, C, Hirawat, S, Juric, D
Published in Annals of oncology (01.10.2018)
Published in Annals of oncology (01.10.2018)
Get full text
Journal Article
Abstract P4-22-16: First-line ribociclib + letrozole in patients with HR+, HER2– advanced breast cancer (ABC) presenting with visceral metastases or bone-only disease: A subgroup analysis of the MONALEESA-2 trial
Burris, HA, Chan, A, Campone, M, Blackwell, KL, Winer, EP, Janni, W, Verma, S, Burdaeva, O, Alba, E, Favret, AM, Mondal, S, Miller, M, Germa, C, Hirawat, S, Yap, YS
Published in Cancer research (Chicago, Ill.) (15.02.2017)
Published in Cancer research (Chicago, Ill.) (15.02.2017)
Get full text
Journal Article
Abstract P4-22-18: Phase Ib safety, efficacy, and molecular analysis of ribociclib (LEE011) plus letrozole for the treatment of ER+, HER2– advanced breast cancer
Munster, P, Ismail-Khan, R, Garcia-Estevez, L, Mayer, IA, Becerra, C, Hamilton, E, De Boer, R, Wardley, AM, Im, S-A, Teixeira, L, Wang, Y, Su, F, Germa, C, Hirawat, S, Juric, D
Published in Cancer research (Chicago, Ill.) (15.02.2017)
Published in Cancer research (Chicago, Ill.) (15.02.2017)
Get full text
Journal Article
Abstract GS2-05: First-line ribociclib vs placebo with goserelin and tamoxifen or a non-steroidal aromatase inhibitor in premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: Results from the randomized phase III MONALEESA-7 trial
Tripathy, D, Sohn, J, Im, S-A, Colleoni, M, Franke, F, Bardia, A, Harbeck, N, Hurvitz, S, Chow, L, Lee, KS, Campos-Gomez, S, Villanueva Vazquez, R, Jung, KH, Carlson, G, Hughes, G, Diaz-Padilla, I, Germa, C, Hirawat, S, Lu, Y-S
Published in Cancer research (Chicago, Ill.) (15.02.2018)
Published in Cancer research (Chicago, Ill.) (15.02.2018)
Get full text
Journal Article
Abstract P4-14-25: Single agent and combined targeting of PI3K, mTOR, HER2 and ER signaling in a panel of HER2+/ER+ versus HER2+/ER- breast cancer cell lines
O'Brien, NA, Nichols, CM, Thomas, J, Conklin, D, Kalous, O, Linnartz, R, Di Tomasso, E, Hurvitz, SA, Hirawat, S, Slamon, DJ
Published in Cancer research (Chicago, Ill.) (15.02.2016)
Published in Cancer research (Chicago, Ill.) (15.02.2016)
Get full text
Journal Article